OncoMatch/Clinical Trials/NCT07218809
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Is NCT07218809 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for epithelial ovarian cancer.
Treatment: AZD5335 · Mirvetuximab Soravtansine (MIRV) · Paclitaxel · Pegylated liposomal Doxorubicin (PLD) · Topotecan — The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented contraindication, precaution or intolerance.
Allowed: BRCA2 mutation
Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented contraindication, precaution or intolerance.
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Participants must have platinum-resistant disease
Cannot have received: FRα-targeted therapy (mirvetuximab soravtansine)
Prior treatment with any FRα-targeted therapy, including MIRV
Cannot have received: TOP1i antibody-drug conjugate
Prior treatment with any TOP1i ADC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Fort Lauderdale, Florida
- Research Site · Jupiter, Florida
- Research Site · Evanston, Illinois
- Research Site · Peoria, Illinois
- Research Site · Urbana, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07218809 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FRα-targeted therapy, TOP1i antibody-drug conjugate disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages